These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 11856079

  • 1. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC.
    Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
    [Abstract] [Full Text] [Related]

  • 2. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
    Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD.
    Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK.
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [Abstract] [Full Text] [Related]

  • 4. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK.
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [Abstract] [Full Text] [Related]

  • 5. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
    Loftus EV, Kane SV, Bjorkman D.
    Aliment Pharmacol Ther; 2004 Jan 15; 19(2):179-89. PubMed ID: 14723609
    [Abstract] [Full Text] [Related]

  • 6. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB, Goa KL.
    Drugs; 2002 Jan 15; 62(11):1689-705. PubMed ID: 12109930
    [Abstract] [Full Text] [Related]

  • 7. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day.
    Giaffer MH, Holdsworth CD, Lennard-Jones JE, Rodrigues CA, McIntyre PB, Manjunatha S, Baron JH, Barrison IG, Polson RJ, Hoare AM.
    Aliment Pharmacol Ther; 1992 Aug 15; 6(4):479-85. PubMed ID: 1358234
    [Abstract] [Full Text] [Related]

  • 8. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
    Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD.
    Gastroenterology; 1998 Jan 15; 114(1):15-22. PubMed ID: 9428213
    [Abstract] [Full Text] [Related]

  • 9. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W, Schreiber S, Theuer D, Brandes JW, Schütz E, Howaldt S, Krakamp B, Hämling J, Mönnikes H, Koop I, Stolte M, Pallant D, Ewald U.
    Gut; 2001 Dec 15; 49(6):783-9. PubMed ID: 11709512
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE, Kane S.
    Rev Gastroenterol Disord; 2004 Dec 15; 4(2):86-91. PubMed ID: 15185719
    [Abstract] [Full Text] [Related]

  • 15. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
    Kles KA, Vavricka SR, Turner JR, Musch MW, Hanauer SB, Chang EB.
    Inflamm Bowel Dis; 2005 Mar 15; 11(3):253-7. PubMed ID: 15735431
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, Mareya S, Forbes WP.
    Am J Gastroenterol; 2009 Jun 15; 104(6):1452-9. PubMed ID: 19491859
    [Abstract] [Full Text] [Related]

  • 18. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
    Edmond LM, Hopkins MJ, Magee EA, Cummings JH.
    Inflamm Bowel Dis; 2003 Jan 15; 9(1):10-7. PubMed ID: 12656132
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.
    Nikfar S, Rahimi R, Rezaie A, Abdollahi M.
    Dig Dis Sci; 2009 Jun 15; 54(6):1157-70. PubMed ID: 18770034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.